CD274 and neoplasm: Numerous biomarkers, including PD-L1 expression level, TMB, and tumor-infiltrating immune cells (e.g., T and B cell subgroups), are being tested in various clinical practice settings as predictors of ICI response20,21,22,23; however, their predictive performances were mainly demonstrated in the first-line setting and suffered when used alone.